TR200403256T3 - İnsan ürokinaz plasminojen aktifleyici genini içeren viral ve non-viral rekombinant vektörler ve bunların çeşitli tipteki karaciğer, böbrek, akciğer, pankreas ve kalp fibröz dejenerasyonları ve hipertrofik skarlarının tedavisinde kullanılması - Google Patents

İnsan ürokinaz plasminojen aktifleyici genini içeren viral ve non-viral rekombinant vektörler ve bunların çeşitli tipteki karaciğer, böbrek, akciğer, pankreas ve kalp fibröz dejenerasyonları ve hipertrofik skarlarının tedavisinde kullanılması

Info

Publication number
TR200403256T3
TR200403256T3 TR2004/03256T TR200403256T TR200403256T3 TR 200403256 T3 TR200403256 T3 TR 200403256T3 TR 2004/03256 T TR2004/03256 T TR 2004/03256T TR 200403256 T TR200403256 T TR 200403256T TR 200403256 T3 TR200403256 T3 TR 200403256T3
Authority
TR
Turkey
Prior art keywords
viral
kidney
lung
liver
heart
Prior art date
Application number
TR2004/03256T
Other languages
English (en)
Inventor
Armendariz Borunda Juan
Aguilar Cordova Estuardo
Original Assignee
Tgt Laboratories, S.A. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tgt Laboratories, S.A. De C.V. filed Critical Tgt Laboratories, S.A. De C.V.
Publication of TR200403256T3 publication Critical patent/TR200403256T3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Bulus rekombinant adeno-viral ve non-adeno-viral vektörlerin hazirlanmasi için bir yönteme iliskin olup, özelligi insanlar dahil memelilerdeki karaciger, akciger, kalp, böbrek, pankreas fibroz dejenerasyonlari, keloidleri ve hipertrofik skarlarinin tedavisi için terapötik proteinleri kodlayan cDNA ile muhabir genlerinin klonlanmasini içermesidir. Bulus ayrica bunlarin çesitli tipteki karaciger, böbrek, akciger, pankreas ve kalp fibroz dejenerasyonlari ile hipertrofik skarlarinin tedavisinde kullanilmasina iliskindir.
TR2004/03256T 2000-11-28 2000-11-30 İnsan ürokinaz plasminojen aktifleyici genini içeren viral ve non-viral rekombinant vektörler ve bunların çeşitli tipteki karaciğer, böbrek, akciğer, pankreas ve kalp fibröz dejenerasyonları ve hipertrofik skarlarının tedavisinde kullanılması TR200403256T3 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA00011713A MXPA00011713A (es) 2000-11-28 2000-11-28 Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe

Publications (1)

Publication Number Publication Date
TR200403256T3 true TR200403256T3 (tr) 2005-02-21

Family

ID=32294070

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/03256T TR200403256T3 (tr) 2000-11-28 2000-11-30 İnsan ürokinaz plasminojen aktifleyici genini içeren viral ve non-viral rekombinant vektörler ve bunların çeşitli tipteki karaciğer, böbrek, akciğer, pankreas ve kalp fibröz dejenerasyonları ve hipertrofik skarlarının tedavisinde kullanılması

Country Status (15)

Country Link
US (1) US7807457B2 (tr)
EP (1) EP1411128B1 (tr)
JP (1) JP4733337B2 (tr)
AR (1) AR031436A1 (tr)
AT (1) ATE409234T1 (tr)
AU (1) AU2001217374A1 (tr)
CA (1) CA2430367C (tr)
CY (1) CY1108667T1 (tr)
DE (2) DE60040352D1 (tr)
DK (1) DK1411128T3 (tr)
ES (1) ES2226597T3 (tr)
MX (1) MXPA00011713A (tr)
PT (1) PT1411128E (tr)
TR (1) TR200403256T3 (tr)
WO (1) WO2002044393A1 (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569342B2 (en) 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
US7247620B2 (en) 2001-05-09 2007-07-24 Anges Mg, Inc. Method of treating skin wounds with vectors encoding hepatocyte growth factor
WO2007094071A1 (ja) * 2006-02-17 2007-08-23 Tokyo University Of Agriculture And Technology Tlo Co., Ltd. 肝機能改善剤
WO2013032918A1 (en) 2011-08-26 2013-03-07 Yecuris Corporation Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof
PL3320901T3 (pl) * 2016-01-28 2020-07-13 Accendatech Dimetyloaminomicheliolid do zastosowania w leczeniu włóknienia płuc
EP3468605A4 (en) * 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS
CN108210899A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗组织器官纤维化的药物及其用途
US11219669B2 (en) 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
AU2018364542A1 (en) 2017-11-08 2020-04-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
WO2020140101A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
WO1993024640A2 (en) * 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
DE4339922C1 (de) * 1993-09-03 1994-10-06 Max Planck Gesellschaft Vektor für Leber-Gentherapie
US6686198B1 (en) * 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5980886A (en) * 1994-12-14 1999-11-09 University Of Washington Recombinant vectors for reconstitution of liver
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6265212B1 (en) * 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1997017090A1 (en) * 1995-11-07 1997-05-15 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
ES2289778T3 (es) 1997-04-18 2008-02-01 Biogen Idec Ma Inc. Proteinas de fusion de la region constante de la inmunoglobulina/receptor tgf-beta tipo ii.
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
AU3774499A (en) * 1998-04-29 1999-11-16 Uab Research Foundation, The Adenoviral vector encoding anti-apoptotic bcl-2 gene and uses thereof

Also Published As

Publication number Publication date
DE60040352D1 (de) 2008-11-06
WO2002044393A1 (es) 2002-06-06
HK1062454A1 (en) 2004-11-05
ES2226597T3 (es) 2009-03-16
EP1411128A1 (en) 2004-04-21
DE00980071T1 (de) 2005-03-31
ATE409234T1 (de) 2008-10-15
US7807457B2 (en) 2010-10-05
CA2430367A1 (en) 2002-06-06
US20040097455A1 (en) 2004-05-20
CA2430367C (en) 2012-10-30
MXPA00011713A (es) 2002-05-31
PT1411128E (pt) 2008-12-30
AR031436A1 (es) 2003-09-24
DK1411128T3 (da) 2009-02-02
CY1108667T1 (el) 2014-04-09
AU2001217374A1 (en) 2002-06-11
ES2226597T1 (es) 2005-04-01
JP2004527224A (ja) 2004-09-09
JP4733337B2 (ja) 2011-07-27
EP1411128B1 (en) 2008-09-24

Similar Documents

Publication Publication Date Title
Boffa et al. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties
ES2263199T3 (es) Analogos del factor x con un sitio de ruptura de proteasa modificado.
Rezaie Regulation of the protein C anticoagulant and antiinflammatory pathways
US7700734B2 (en) Recombinant human factor IX and use thereof
ATE279938T1 (de) Reduktion des gewebe-volumens
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
DE60323078D1 (de) Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine
WO2003066824A3 (en) Albumin-fused kunitz domain peptides
AU732953B2 (en) Factor X deletion mutants and analogues thereof
MXPA06001173A (es) Metodo analitico para la pancreatina y composiciones comparables.
DE60233047D1 (de) Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
ES2042693T5 (es) Formulaciones de proteinas plasmaticas y recombinantes en medios de baja potencia ionica.
WO2003023000A3 (en) Linear dna fragments for gene expression
EP0973538A4 (en) MODIFIED PROTEINS BINDING TO EXTRACELLULAR MATRIX COMPONENTS
CY1108667T1 (el) Ανασυνδυασμενοι φορεις ιου περιεχοντες το ανθρωπινο γονιδιο του ενεργοποιητη πλασμινογονου ουροκινασης και η χρηση τους στην αγωγη της ινωσεως του ηπατος.
DK1278868T3 (da) Muteret form af arginindeiminase
Laug Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells
NO20021501L (no) Fibrinolyttisk aktivt polypeptid
ES2302696T3 (es) Analogo de factor x con mejor capacidad de activacion.
JP2006516113A5 (tr)
EP1613345A4 (en) COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320
WO2001021761A3 (es) Vectores adenovirales recombinantes y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar y cicatrices hipertroficas
WO2002002148A3 (en) Dual recombinant gene therapy compositions and methods of use
DE60044038D1 (de) Xylosyltransferase und isoformen
ATE292177T1 (de) Gentherapy von lungenkrankheiten